azathioprine has been researched along with Aortic Arteritis, Giant Cell in 26 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ability of azathioprine to reduce the maintenance prednisolone requirement of 31 patients with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), or both, was tested in a double-blind placebo controlled study over one year." | 9.06 | Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. ( De Silva, M; Hazleman, BL, 1986) |
| "The aim of this bicentric retrospective study was to describe the use of azathioprine in giant cell arteritis, and to appreciate its corticosteroid-sparing effect in glucocorticoid-dependent patients or with severe glucocorticoid related side effects." | 7.83 | [Place of azathioprine in the treatment of giant cell arteritis]. ( Agard, C; Boureau, AS; De Decker, L; de Faucal, P; Espitia, O, 2016) |
| "The ability of azathioprine to reduce the maintenance prednisolone requirement of 31 patients with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), or both, was tested in a double-blind placebo controlled study over one year." | 5.06 | Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. ( De Silva, M; Hazleman, BL, 1986) |
| "The aim of this bicentric retrospective study was to describe the use of azathioprine in giant cell arteritis, and to appreciate its corticosteroid-sparing effect in glucocorticoid-dependent patients or with severe glucocorticoid related side effects." | 3.83 | [Place of azathioprine in the treatment of giant cell arteritis]. ( Agard, C; Boureau, AS; De Decker, L; de Faucal, P; Espitia, O, 2016) |
| "Giant cell arteritis is a chronic vasculitis affecting large and medium-sized arteries, most commonly the temporal and other cranial arteries." | 2.48 | Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. ( Borchers, AT; Gershwin, ME, 2012) |
| "Clinicians who treat patients with giant cell arteritis (GCA) face many unresolved challenges." | 2.44 | Five clinical conundrums in the management of giant cell arteritis. ( Cid, MC; Espígol-Frigolé, G; García-Martínez, A; Hernández-Rodríguez, J; Lozano, E, 2007) |
| " To achieve maximal efficacy but minimize glucocorticoid-related adverse reactions, dosage should be individually tailored." | 2.44 | Improving therapeutic options for patients with giant cell arteritis. ( Pipitone, N; Salvarani, C, 2008) |
| "When unrecognized and therefore untreated, vasculitis of the nervous system leads to pervasive injury and disability making this a disorder of paramount importance to all clinicians." | 2.42 | Vasculitis of the nervous system. ( Younger, DS, 2004) |
| "Polymyalgia rheumatica (PMR)/temporal arteritis (TA) frequently causes significant morbidity in patients older than 50 years of age." | 2.41 | Polymyalgia rheumatica/temporal arteritis: recent advances. ( Barilla-LaBarca, ML; Brasington, RD; Lenschow, DJ, 2002) |
| "Corticosteroids remain the cornerstone treatment of giant cell arteritis." | 2.40 | [Immunosuppressive agents in Horton's disease. Which drug for which indication?]. ( Roblot, P, 1998) |
| "He had been diagnosed with temporal arteritis 12 years earlier." | 1.48 | Hypertrophic pachymeningoencephalitis associated with temporal giant cell arteritis. ( Boisch, G; Duda, S; Hartmann, C; Weßling, H, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (26.92) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 9 (34.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boisch, G | 1 |
| Duda, S | 1 |
| Hartmann, C | 1 |
| Weßling, H | 1 |
| Samson, M | 2 |
| Greigert, H | 1 |
| Ghesquière, T | 1 |
| Bonnotte, B | 1 |
| Boureau, AS | 1 |
| de Faucal, P | 1 |
| Espitia, O | 1 |
| De Decker, L | 1 |
| Agard, C | 1 |
| Watelet, B | 1 |
| de Boysson, H | 1 |
| Bienvenu, B | 1 |
| Muratore, F | 1 |
| Pipitone, N | 2 |
| Salvarani, C | 2 |
| Cantoni, N | 1 |
| Meyer, P | 1 |
| Katan, M | 1 |
| Kappos, L | 2 |
| Hess, C | 1 |
| Daikeler, T | 1 |
| McWilliams, ET | 1 |
| Dickinson, KK | 1 |
| Walker, DM | 1 |
| Raman, V | 1 |
| Borchers, AT | 1 |
| Gershwin, ME | 1 |
| Moll, R | 1 |
| Hameed, B | 1 |
| Schnabel, A | 1 |
| Roelcke, U | 1 |
| Eschle, D | 1 |
| Moschopulos, M | 1 |
| Laeng, RH | 1 |
| Buettner, UW | 1 |
| Younger, DS | 1 |
| Cid, MC | 1 |
| García-Martínez, A | 1 |
| Lozano, E | 1 |
| Espígol-Frigolé, G | 1 |
| Hernández-Rodríguez, J | 1 |
| Kaeser, HE | 1 |
| Roblot, P | 1 |
| Barilla-LaBarca, ML | 1 |
| Lenschow, DJ | 1 |
| Brasington, RD | 1 |
| Airò, P | 1 |
| Antonioli, CM | 1 |
| Vianelli, M | 1 |
| Toniati, P | 1 |
| Hoffman, GS | 1 |
| Alexander, M | 1 |
| Kampf, D | 1 |
| Lovschall, S | 1 |
| Wenig, C | 1 |
| Meiser, RJ | 1 |
| Roig López de los Mozos, A | 1 |
| Calvo Catalá, J | 1 |
| Hortelano Martínez, E | 1 |
| Liñana Santafé, JJ | 1 |
| González-Cruz Cervellera, MI | 1 |
| Ballester Belda, JE | 1 |
| De Silva, M | 1 |
| Hazleman, BL | 1 |
| Sölch, G | 1 |
| Kiesewetter, R | 1 |
| Kaiser, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO[NCT03841734] | Phase 3 | 8 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for azathioprine and Aortic Arteritis, Giant Cell
| Article | Year |
|---|---|
[Treatment of giant cell arteritis].
Topics: Abatacept; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Azat | 2019 |
Treatment of giant-cell arteritis, a literature review.
Topics: Antirheumatic Agents; Azathioprine; Drug Therapy, Combination; Drug-Related Side Effects and Adverse | 2017 |
Standard and biological treatment in large vessel vasculitis: guidelines and current approaches.
Topics: Animals; Antibodies, Monoclonal; Azathioprine; Biological Therapy; Clinical Trials as Topic; Giant C | 2017 |
Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment.
Topics: Aorta; Aortic Aneurysm; Aspirin; Azathioprine; Dendritic Cells; Female; Giant Cell Arteritis; Humans | 2012 |
Vasculitis of the nervous system.
Topics: Azathioprine; Connective Tissue Diseases; Cyclophosphamide; Diagnosis, Differential; Giant Cell Arte | 2004 |
Five clinical conundrums in the management of giant cell arteritis.
Topics: Abortifacient Agents, Nonsteroidal; Aorta; Aortography; Azathioprine; Dilatation, Pathologic; Giant | 2007 |
Improving therapeutic options for patients with giant cell arteritis.
Topics: Antibodies, Monoclonal; Azathioprine; Dose-Response Relationship, Drug; Drug Administration Schedule | 2008 |
[Immunosuppressive agents in Horton's disease. Which drug for which indication?].
Topics: Anti-Inflammatory Agents; Azathioprine; Drug Resistance; Giant Cell Arteritis; Humans; Immunosuppres | 1998 |
Polymyalgia rheumatica/temporal arteritis: recent advances.
Topics: Adrenal Cortex Hormones; Aged; Azathioprine; Cyclophosphamide; Dose-Response Relationship, Drug; Dru | 2002 |
Treatment of giant-cell arteritis: where we have been and why we must move on.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Aortic Aneurysm; Azathioprine; Drug Therapy, Combina | 2002 |
2 trials available for azathioprine and Aortic Arteritis, Giant Cell
| Article | Year |
|---|---|
Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs.
Topics: Aged; Antibodies, Monoclonal; Antirheumatic Agents; Azathioprine; Drug Resistance; Drug Therapy, Com | 2002 |
Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.
Topics: Aged; Azathioprine; Clinical Trials as Topic; Double-Blind Method; Female; Giant Cell Arteritis; Hum | 1986 |
14 other studies available for azathioprine and Aortic Arteritis, Giant Cell
| Article | Year |
|---|---|
Hypertrophic pachymeningoencephalitis associated with temporal giant cell arteritis.
Topics: Aged, 80 and over; Antirheumatic Agents; Azathioprine; Craniotomy; Diagnosis, Differential; Dura Mat | 2018 |
[Place of azathioprine in the treatment of giant cell arteritis].
Topics: Aged; Aged, 80 and over; Azathioprine; Drug Resistance; Female; France; Giant Cell Arteritis; Humans | 2016 |
A confusing patient's history: small or large vessel vasculitis?
Topics: Autoantibodies; Azathioprine; Conjunctivitis; Cyclophosphamide; Diagnosis, Differential; Drug Therap | 2010 |
Acute inflammatory aortitis: utility of hybrid imaging with positron emission tomography/computed tomography in diagnosis and follow-up.
Topics: Acute Disease; Aortitis; Azathioprine; Biopsy; Drug Therapy, Combination; Female; Fluorodeoxyglucose | 2012 |
A case of Takayasu arteritis diagnosed at early-phase of disease by conventional CT scanning.
Topics: Adult; Aorta; Aortitis; Atherosclerosis; Azathioprine; Behcet Syndrome; Diagnosis, Differential; Dos | 2012 |
[Corticosteroid saving-up in giant cell arteritis?].
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Azathioprine; Cycloph | 2002 |
Meningoradiculitis associated with giant cell arteritis.
Topics: Anti-Inflammatory Agents; Azathioprine; Cranial Nerve Diseases; Cyclophosphamide; Giant Cell Arterit | 2002 |
Cytostatic drugs in the treatment of severe vasculitides. Indications, results and risks.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Azathioprine; Cyclophosphamide; Drug Therapy, Combin | 1984 |
[Hyperergic collagenoses. Clinical aspects, differential diagnosis and therapy (author's transl)].
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Child; Collagen Diseases; Cyclophosphamide; Derm | 1977 |
[Azathioprine in the treatment of temporal arteritis and polymyalgia rheumatica].
Topics: Aged; Azathioprine; Back Pain; Drug Evaluation; Drug Therapy, Combination; Female; Fractures, Sponta | 1977 |
[Azathioprine in the treatment of arteriitis temporalis].
Topics: Aged; Autoimmune Diseases; Azathioprine; Dose-Response Relationship, Drug; Drug Therapy, Combination | 1975 |
[Immunosuppressor treatment in temporal arteritis of long-term evolution].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chronic Disease; Female; Giant Cell Art | 1992 |
[Temporal arteritis--inflammatory vascular disease of the higher age].
Topics: Age Factors; Aged; Anticoagulants; Azathioprine; Blindness; Female; Giant Cell Arteritis; Humans; Pr | 1974 |
[Polymyalgia rheumatica].
Topics: Age Factors; Aged; Autoimmune Diseases; Azathioprine; Biopsy; Female; Giant Cell Arteritis; Humans; | 1974 |